Dyne Therapeutics (DYN)Chief Commercial Officer sold ~$1.9K

~$1.9K

Approx. value · 144 sh @ $13.41

95K

Holds after · shares reported

Traded

Sep 5, 2025

Filed

Sep 8, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jul 14, 2025InsiderCEO purchased ~$911K of DYN shares in the open market
2. Sep 4, 2025Insider · 2 peopleInsiders: 2 sales (~$59K)
3. Sep 5, 2025 · this disclosureInsiderOfficer sold ~$1.9K of DYN shares in the open market

What came next

1. Sep 5, 2025Insider · 2 peopleInsiders: 2 sales (~$47K)
2. Oct 1, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 1, 2025, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Brian Posner as a Class III director to serve on the Board until the Company’s 2026 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or…”
3. Nov 5, 2025Company filing · Form 8-K · ResultsReported its results
4. Dec 8, 2025Company filing · Form 8-K · New debtTook on new debt or obligations
5. Dec 9, 2025Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
6. Dec 22, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 22, 2025, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Vikram Karnani as a Class II director to serve on the Board until the Company’s 2028 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or…”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Dyne Therapeutics

For Dyne Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 6 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DYN page.

Other recent filings by Johanna Friedl-naderer, Chief Commercial Officer

• SEC Form 4 at Dyne Therapeutics (DYN)Sep 8, 2025
• SEC Form 4 at Dyne Therapeutics (DYN)Jun 6, 2025
• SEC Form 4 at Dyne Therapeutics (DYN)Mar 13, 2025

The full history of Johanna Friedl-naderer, Chief Commercial Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Dyne Therapeutics

• SEC Form 4Oct 7, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its DYN page.